Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8733706 | Critical Reviews in Oncology/Hematology | 2018 | 9 Pages |
Abstract
In this paper, we show that, for diffuse low-grade glioma, some specificities - dual goal of both survival and functional gain, long duration of the disease with multistep treatments, multiparametric evaluation of the onco-functional balance of each treatment modality - call for a change of paradigm. After summarizing how to weight the benefits and risks of surgery, chemotherapy and radiotherapy, we show that the overall efficacy of a treatment modality cannot be assessed per se, as it depends on its integration in the whole sequence. Then, we revisit the notion of personalized medicine: instead of decision-making based solely on molecular profile, we plead for a recursive algorithm, allowing a dynamic evaluation of the onco-functional balance, integrating many individual characteristics of the patient's tumor and brain function.
Related Topics
Health Sciences
Medicine and Dentistry
Hematology
Authors
Emmanuel Mandonnet, Hugues Duffau,